Jubilant Pharmova Ltd.

NSE: JUBLPHARMA | BSE: 530019 | ISIN: INE700A01033 | Industry: Pharmaceuticals
| Mid-range Performer
1122.3000 -2.30 (-0.20%)
NSE Sep 12, 2025 15:31 PM
Volume: 82,249
 

1122.30
-0.20%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 10% YoY to | 1641 crore (I-direct estimate: | 1644 crore). Revenues in LSI revenues grew 18% YoY to | 782 crore (Idirect estimate: | 697 crore) while the pharma business grew mere 2.4% YoY to | 860 crore (I-direct estimate: | 926 crore) EBITDA margins declined 100 bps YoY to 18.6% (I-direct estimate: 22.4%), adversely impacted mainly due to a change in the product mix and one-off. EBITDA increased 5% YoY to | 305 crore Adjusted net profit grew 283% to | 150 crore (I-direct estimate: | 163...
Jubilant Pharmova Ltd. has gained 29.53% in the last 6 Months
More from Jubilant Pharmova Ltd.
Recommended